{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T13:59:55Z","timestamp":1784642395345,"version":"3.55.0"},"reference-count":15,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1097\/hs9.0000000000000899","type":"journal-article","created":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T13:04:09Z","timestamp":1686229449000},"page":"e899","source":"Crossref","is-referenced-by-count":5,"title":["High-risk Combinations of Additional Chromosomal Abnormalities in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia: JALSG Ph+ALL TKI-SCT Study"],"prefix":"10.1002","volume":"7","author":[{"given":"Satoshi","family":"Nishiwaki","sequence":"first","affiliation":[{"name":"Department of Advanced Medicine, Nagoya University Hospital, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isamu","family":"Sugiura","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Toyohashi Municipal Hospital, Toyohashi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Fujisawa","sequence":"additional","affiliation":[{"name":"Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Hatta","sequence":"additional","affiliation":[{"name":"Department of Hematology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiko","family":"Atsuta","sequence":"additional","affiliation":[{"name":"Japanese Data Center for Hematopoietic Cell Transplantation, Nagakute, Japan"},{"name":"Department of Registry Science for Transplant and Cellular Therapy, Aichi Medical University School of Medicine, Nagakute, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Doki","sequence":"additional","affiliation":[{"name":"Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Kurahashi","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Toyohashi Municipal Hospital, Toyohashi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasunori","family":"Ueda","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Kurashiki Central Hospital, Kurashiki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuaki","family":"Dobashi","sequence":"additional","affiliation":[{"name":"Division of Clinical Oncology\/Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoya","family":"Maeda","sequence":"additional","affiliation":[{"name":"Department of Hemato-Oncology, Saitama Medical University International Medical Center, Saitama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Taniguchi","sequence":"additional","affiliation":[{"name":"Department of Hematology and Rheumatology, Kindai University Faculty of Medicine, Osakasayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatsugu","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Hematology, Kanagawa Cancer Center, Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Kako","sequence":"additional","affiliation":[{"name":"Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuo","family":"Ichinohe","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Fukuda","sequence":"additional","affiliation":[{"name":"Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeki","family":"Ohtake","sequence":"additional","affiliation":[{"name":"Kanazawa University, Kanazawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Ishikawa","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Kiyoi","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itaru","family":"Matsumura","sequence":"additional","affiliation":[{"name":"Department of Hematology and Rheumatology, Kindai University Faculty of Medicine, Osakasayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Miyazaki","sequence":"additional","affiliation":[{"name":"Department of Hematology, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of Japan Adult Leukemia Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,6]]},"reference":[{"key":"R1-20231116","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/ajh.24625","article-title":"Poor outcomes associated with +der(22)t(9;22) and -9\/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor.","volume":"92","author":"Short","year":"2017","journal-title":"Am J Hematol"},{"key":"R2-20231116","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.3324\/haematol.2020.260935","article-title":"A multicenter total therapy strategy for de novo adult Philadelphia chromosome positive acute lymphoblastic leukemia patients: final results of the GIMEMA LAL1509 protocol.","volume":"106","author":"Chiaretti","year":"2021","journal-title":"Haematologica"},{"key":"R3-20231116","first-page":"2309","article-title":"Adult Ph-positive acute lymphoblastic leukemia-current concepts in cytogenetic abnormalities and outcomes.","volume":"10","author":"Shi","year":"2020","journal-title":"Am J Cancer Res"},{"key":"R4-20231116","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1200\/JCO.2005.03.2177","article-title":"High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group.","volume":"24","author":"Yanada","year":"2006","journal-title":"J Clin Oncol"},{"key":"R5-20231116","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/ajh.24653","article-title":"Phase II study of imatinib-based chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia.","volume":"92","author":"Fujisawa","year":"2017","journal-title":"Am J Hematol"},{"key":"R6-20231116","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1182\/bloodadvances.2021004607","article-title":"Dasatinib-based 2-step induction for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.","volume":"6","author":"Sugiura","year":"2022","journal-title":"Blood Adv"},{"key":"R7-20231116","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1046\/j.1365-2141.2003.04736.x","article-title":"Additional cytogenetic abnormalities in adults with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a study of the Cancer and Leukaemia Group B.","volume":"124","author":"Wetzler","year":"2004","journal-title":"Br J Haematol"},{"key":"R8-20231116","doi-asserted-by":"crossref","first-page":"4153","DOI":"10.1182\/blood-2008-11-185132","article-title":"Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL).","volume":"113","author":"Bassan","year":"2009","journal-title":"Blood"},{"key":"R9-20231116","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/j.bbmt.2015.03.021","article-title":"Impact of additional cytogenetic abnormalities in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia undergoing allogeneic hematopoietic cell transplantation.","volume":"21","author":"Aldoss","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"R10-20231116","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1182\/blood-2016-02-700153","article-title":"Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL.","volume":"128","author":"Rousselot","year":"2016","journal-title":"Blood"},{"key":"R11-20231116","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1016\/j.bbmt.2018.06.006","article-title":"Additional cytogenetic abnormalities with Philadelphia chromosome-positive acute lymphoblastic leukemia on allogeneic stem cell transplantation in the tyrosine kinase inhibitor Era.","volume":"24","author":"Akahoshi","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"R12-20231116","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/sj.leu.2403324","article-title":"Secondary cytogenetic aberrations in childhood Philadelphia chromosome positive acute lymphoblastic leukemia are nonrandom and may be associated with outcome.","volume":"18","author":"Heerema","year":"2004","journal-title":"Leukemia"},{"key":"R13-20231116","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S1470-2045(15)00207-7","article-title":"Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study.","volume":"16","author":"Jabbour","year":"2015","journal-title":"Lancet Oncol"},{"key":"R14-20231116","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa2016272","article-title":"Dasatinib-Blinatumomab for Ph-positive acute lymphoblastic leukemia in adults.","volume":"383","author":"Fo\u00e0","year":"2020","journal-title":"N Engl J Med"},{"key":"R15-20231116","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/s41375-021-01448-2","article-title":"Prognostic impact of chromosomal abnormalities and copy number alterations in adult B-cell precursor acute lymphoblastic leukaemia: a UKALL14 study.","volume":"36","author":"Moorman","year":"2022","journal-title":"Leukemia"}],"container-title":["HemaSphere"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/HS9.0000000000000899","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T18:06:52Z","timestamp":1702922812000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/HS9.0000000000000899"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":15,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/hs9.0000000000000899","relation":{},"ISSN":["2572-9241"],"issn-type":[{"value":"2572-9241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6]]}}}